Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAdvanced Oncotherapy Regulatory News (AVO)

  • This share is currently suspended. It was suspended at a price of 1.925

Share Price Information for Advanced Oncotherapy (AVO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.925
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1.925
AVO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Collaboration with Spire Healthcare

20 Aug 2013 07:00

RNS Number : 0392M
Advanced Oncotherapy PLC
20 August 2013
 



20 August 2013

 

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or "the Group")

 

Collaboration with Spire Healthcare to offer patients a new type of cancer treatment in three Spire Hospitals in the UK

 

Advanced Oncotherapy today announces that they have signed a letter of intent with Spire Healthcare Limited ("Spire") to bring more affordable proton radiotherapy to the UK. This agreement will enable Spire to further expand, and complement, its existing range of oncology services.

 

Advanced Oncotherapy's patented technology makes proton beam therapy for cancer treatment more affordable. Their state of the art proton beam machine is based on LIGHT technology - Linac Image Guided Hadron Technology - a direct medical application of high energy particle physics research by ADAM, which Advanced Oncotherapy is in the process of acquiring, at CERN (The Large Hadron Collider).

 

Proton radiotherapy is at the forefront of the fight against cancer, but the UK lags behind its US and European counterparts, despite the government having recently announced funding for two NHS proton radiotherapy centres in London and Manchester. Protons are established as being a much more accurate form of treatment than conventional radiotherapy, causing far fewer side effects. However, previously, machines have been prohibitively expensive.

 

With the new LIGHT machine at Spire hospitals, costs will be substantially cheaper, and patients benefit from easy access, convenient locations, and the ability to treat cancers more precisely. This represents a game-changing new treatment option for cancer patients in the UK, and underpins the commitment of both companies to high quality, affordable and innovative care.

 

Advanced Oncotherapy's CEO, Dr Mike Sinclair, said, "We have long been sure that this technology has the potential to bring the benefits of proton beam therapy to many more cancer patients than is possible currently. Our belief has been endorsed by one of the private sector's largest and most forward thinking hospital groups. We are delighted to partner with Spire Healthcare for these new exciting centres".

 

Rob Roger, Spire Healthcare's Chief Executive, added, "We are delighted to be working with Advanced Oncotherapy on the development of a new delivery system for proton beam therapy. This reinforces our position as a provider of affordable high quality cancer care throughout our network of hospitals".

 

For further information, please visit www.advancedoncotherapy.com or contact:

 

Michael Sinclair,

Chief Executive

Sandy Jamieson

Jon Levinson/

Lucy Williams

Simon Hudson

Advanced

Oncotherapy Plc

Libertas Capital

Corporate Finance Ltd

Peterhouse

Corporate Finance

Tavistock Communications

(NOMAD & Joint Broker)

(Joint Broker)

(Financial PR & IR)

+44 20 3617 8739

+44 20 3697 9495

+44 20 7469 0930

+44 20 7920 3150

 

About Advanced Oncotherapy Plc

1. AVO is a provider of radiotherapy services that harnesses the best in modern technology. As a result, we offer cancer patients affordable access to innovative treatments with proven better health outcomes.

 

2. AVO's acquisition of ADAM, a company spin off from CERN (The Large Hadron Collider), focuses on the development of a proprietary radiation technology called LIGHT. This technology offers patients and providers the benefits of proton beam therapy at significantly reduced capital and running costs.

 

3. AVO's subsidiary company, Oncotherapy Resources Ltd, offers an exclusive mobile service for intraoperative radiotherapy (SD-IORT). This form of radiotherapy is used in a variety of cancers, notably breast cancer, and offers a convenient, safe and effective alternative for the patient. It is currently available in the UK through Spire and other hospitals.

 

About Spire Healthcare Limited

Spire Healthcare is one of the UK's largest private hospital providers with 38 hospitals and 11 clinics nationwide. The company is founded on a 30 year heritage of operating successful private hospitals and offers a full range of integrated surgical, medical and diagnostic services.

 

The company was formed from the sale of BUPA Hospitals to private equity company Cinven in 2007, followed by the purchase of Classic Hospitals and Thames Valley Hospital in 2008. Spire has since built Spire Shawfair Park Hospital (Edinburgh), the Montefiore Hospital, acquired London Fertility Centre, and Lifescan. Since Spire was formed, performance improvements have included:

 

· Multiple Independent Healthcare Awards: 'Medical Practice' (2012) 'Innovation' (2011), 'Risk Management' and 'Nursing Practice' (2010), 'Nursing Practice' (2009), and 'Healthcare Outcomes' (2008)

· Increase in percentage of patients rating Spire 'excellent' or 'very good' - from 87% in 2008 to 92% in 2012*

· Increase in percentage of consultant surgeons rating Spire 'excellent' or 'very good' - from 51% in 2008 to 78% in 2012*

· Increase in percentage of employees who think Spire is a 'great place to work' - from 62% in 2009 to 78% in 2012

* Rating options include 'excellent', 'very good', 'quite good', 'quite poor', 'very poor' and 'totally unacceptable'

 

For further information please visit: www.spirehealthcare.com.

 

-ends-

 

 

 

 

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCQKLFFXVFXBBD
Date   Source Headline
2nd Apr 20243:50 pmRNSFurther update on financing discussions
29th Feb 20245:19 pmRNSFurther update on financing discussions
1st Feb 20247:00 amRNSFurther update on financing discussions
9th Jan 20249:00 amRNSUpdate on Financing Discussions
23rd Oct 20237:00 amRNSUpdate on Financing and Current Financial Position
17th Jul 20237:00 amRNSRecapitalisation and funding plan, update on FSP
30th Jun 20235:00 pmRNSTotal Voting Rights
30th Jun 20237:30 amRNSSuspension - Advanced Oncotherapy PLC
30th Jun 20237:15 amRNSUpdate on financing, suspension of trading on AIM
29th Jun 20231:35 pmRNSHolding(s) in Company
29th Jun 20239:59 amRNSForm 8.3 - Advanced Oncotherapy PLC
28th Jun 202310:25 amRNSForm 8.3 - Advanced Oncotherapy PLC
27th Jun 202310:29 amRNSForm 8.3 - Advanced Oncotherapy
27th Jun 202310:25 amRNSForm 8.3 - Advanced Oncotherapy
26th Jun 20234:26 pmRNSForm 8.3 - Advanced Oncotherapy
26th Jun 202310:57 amRNSPartial conversion of Convertible Notes
23rd Jun 202311:05 amRNSHolding(s) in Company
23rd Jun 20239:30 amRNSForm 8.3 - Advanced Oncotherapy PLC
20th Jun 20235:28 pmRNSHolding(s) in Company
19th Jun 20235:56 pmRNSPartial conversion of Convertible Notes
19th Jun 20231:48 pmRNSForm 8.3 - Advanced Oncotherapy PLC
16th Jun 20236:23 pmRNSIssue of warrants
13th Jun 202311:46 amRNSForm 8.3 - Advanced Oncotherapy PLC
31st May 20235:57 pmRNSUpdate on financing and convertible notes
30th May 202310:42 amRNSForm 8.3 - Advanced Oncotherapy Plc
24th May 20235:54 pmRNSForm 8 (OPD) Advanced Oncotherapy plc
24th May 20235:29 pmRNSForm 8.3 - Advanced Oncotherapy - Cosylab d.d.
22nd May 20232:59 pmRNSForm 8.3 - Advanced Oncotherapy plc
19th May 202312:09 pmRNSForm 8.3 - Advanced Oncotherapy PLC
17th May 20232:58 pmRNSForm 8.3 - Advanced Oncotherapy plc
15th May 202311:36 amRNSUpdate on Convertible Note & Loan Extension
15th May 20239:19 amRNSForm 8.3 - Advanced Oncotherapy Plc
12th May 202312:53 pmRNSForm 8.3 - Advanced Oncotherapy - Minmetco Limited
11th May 20235:14 pmRNSForm 8.3 - Advanced Oncotherapy - eQ Blue Planet
11th May 202311:17 amRNSForm 8.3 - Advanced Oncotherapy - Atlantic Cedar
10th May 202311:34 amRNSForm 8.3 - Advanced Oncotherapy plc
9th May 20234:40 pmRNSForm 8.3 - Advanced Oncotherapy - Baltisches Haus
9th May 20234:37 pmRNSForm 8.3 - Advanced Oncotherapy plc
9th May 20234:36 pmRNSForm 8.3 - Advanced Oncotherapy plc
5th May 20238:56 amRNSFORM 8.3 - Advanced Oncotherapy
5th May 20237:00 amRNSAdditional funding from Secured Convertible Note
4th May 20235:01 pmRNSForm 8.3 - Advanced Oncotherapy Plc
4th May 20233:55 pmRNSChange of Registered Office
3rd May 20236:19 pmRNSRule 2.9 Announcement
3rd May 20234:28 pmRNSForm 8.3 - Advanced Oncotherapy PLC
2nd May 20236:19 pmRNSForm 8 (OPD) Advanced Oncotherapy plc
18th Apr 20237:00 amRNSStrategic review and formal sale process
31st Mar 20236:05 pmRNSHolding(s) in Company
20th Mar 202312:36 pmRNSUpdate on Secured Convertible Note Facility
1st Mar 20232:54 pmRNSSecured Convertible Note Facility & other matters

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.